Armando Lira Pineda
Mount Sinai Hospital(US)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy, Fatty Acid Research and Health, Diabetes, Cardiovascular Risks, and Lipoproteins
Most-Cited Works
- → Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk(2019)911 cited
- → Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease(2017)742 cited
- → Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial(2017)665 cited
- → Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial(2017)587 cited
- → Inflammatory and Cholesterol Risk in the FOURIER Trial(2018)264 cited
- → Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score(2019)209 cited
- → Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial(2019)197 cited
- → Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis(2020)178 cited
- → Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin(2017)104 cited
- → Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy(2020)81 cited